Specialists at the London start-up BenevolentAI helped identify the arthritis drug baricitinib, which is now part of a clinical trial
Specialists at the London start-up BenevolentAI helped identify the arthritis drug baricitinib, which is now part of a clinical trial. (Scott Gelber/The New York Times)
©2019 New York Times News Service